Nuvo Group makes INVU, a remote pregnancy monitoring platform that allows high-risk pregnant women to conduct fetal non-stress tests (NSTs) at home rather than in a clinic. The core product is a self-administered wireless sensor band worn from the 32nd week of pregnancy until labor, which captures fetal heart rate, maternal heart rate, and uterine activity, then streams the data to a cloud platform. Clinicians monitor results via a digital dashboard; patients see a simplified summary on a mobile app. Nuvo's key technical claim is that INVU uses both ECG and phonocardiography signals simultaneously, making it more accurate than traditional cardiotocography (CTG) machines, which rely on Doppler ultrasound and have been the standard of care for decades. INVU is FDA-cleared for antepartum home use. Nuvo sells to U.S. healthcare systems, hospital networks, and OB-GYN practice groups, charging a per-pregnancy fee that bundles the sensor band, platform access, and support. Providers bill insurers using standard CPT codes; Nuvo does not bill payers directly. The sensor band is reusable across roughly 12 patients, keeping hardware costs manageable. Nuvo's longer-term goal is to shift toward value-based payer contracts, where Nuvo earns a share of cost savings from reduced hospitalizations and better outcomes. The company has commercial contracts with Banner Health and Sanford Health, and a distribution partnership with Philips. Nuvo is pre-profitability and relies on ongoing capital raises to fund operations.